Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4736048 | 0.91 | ALDH1A1 (0.42) | USP2ALDH1A1LMNATSHRNPSR1 | |
| SCHEMBL11915756 | 0.89 | SLC22A12 (0.47) | ALDH1A1TSHRL3MBTL1RAB9AHPGD | |
| SCHEMBL14700695 | 0.88 | TSHR (0.50) | USP2ALDH1A1LMNATSHRNPSR1 | |
| SCHEMBL4735944 | 0.86 | ALDH1A1 (0.46) | USP2ALDH1A1LMNATSHRNPSR1 | |
| SCHEMBL4736003 | 0.85 | USP2 (0.46) | USP2ALDH1A1LMNATSHRNPSR1 | |
| SCHEMBL1300197 | 0.79 | ALDH1A1 (0.42) | USP2ALDH1A1LMNATSHRNPSR1 | |
| SCHEMBL4736052 | 0.78 | SLC22A12 (0.45) | ALDH1A1HSD17B10MEN1KMT2AHPGD | |
| SCHEMBL10177200 | 0.77 | ALDH1A1 (0.46) | USP2ALDH1A1LMNATSHRHSD17B10 | |
| SCHEMBL14700701 | 0.76 | TSHR (0.53) | USP2ALDH1A1TSHRL3MBTL1RAB9A | |
| SCHEMBL1300441 | 0.76 | PKM (0.46) | USP2ALDH1A1LMNATSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160221969-A1 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20140128338-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128338-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8633232-B2 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130040907-A1 | Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8242154-B2 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242154-B2 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8173690-B2 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173690-B2 | Compounds, compositions and methods of using same for modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2010028190-A2 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20100056464-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056464-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056465-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056465-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056465-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | XDH, PON1, OAT | USP2 1257/4885ALDH1A1 276/4885LMNA 752/4885 |
| US-20140128338-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | XDH, PON1, OAT | USP2 1257/4885ALDH1A1 276/4885LMNA 752/4885 |
| US-20160221969-A1 | Compounds, compositions and methods of using same for modulating uric acid levels | XDH, PON1, OAT | USP2 1257/4885ALDH1A1 276/4885LMNA 752/4885 |
| US-20100056464-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS | XDH, PON1, OAT | USP2 1257/4885ALDH1A1 276/4885LMNA 752/4885 |
| US-20130040907-A1 | Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels | XDH, PON1, OAT | USP2 1257/4885ALDH1A1 276/4885LMNA 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.